研報掘金丨民生證券:恒瑞醫藥創新驅動增長,研發進展不斷,維持“推薦”評級
民生證券研報指出,恒瑞醫藥(600276.SH)創新藥臨牀價值凸顯,驅動收入增長,2023年上半年公司創新藥收入達49.62億元(含税)。上半年內公司仿製藥收入基本持平,手術麻醉、造影等產品以及新上市的仿製藥銷售同比增長較為明顯。為保證創新產出,公司持續加大創新力度,維持較高的研發投入,2023年上半年公司累計研發投入30.58億元,其中費用化研發投入23.31億元。上半年研發管線共有6項上市申請獲NMPA受理,6項臨牀推進至Ⅲ期,17項臨牀推進至Ⅱ期,18項臨牀推進至Ⅰ期。公司創新驅動增長,研發進展不斷,維持“推薦”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.